NYSE:CTLT Catalent - CTLT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Catalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $70.11 +3.11 (+4.64%) (As of 02/7/2023 10:04 AM ET) Add Compare Share Share Today's Range$67.50▼$70.6850-Day Range$42.94▼$67.0052-Week Range$40.69▼$115.33Volume1.01 million shsAverage Volume2.90 million shsMarket Capitalization$12.62 billionP/E Ratio29.96Dividend YieldN/APrice Target$92.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Catalent MarketRank™ ForecastAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside37.9% Upside$92.40 Price TargetShort InterestHealthy3.32% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.53Based on 7 Articles This WeekInsider TradingSelling Shares$72,064 Sold Last QuarterProj. Earnings Growth13.95%From $2.94 to $3.35 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.81 out of 5 starsMedical Sector57th out of 1,027 stocksPharmaceutical Preparations Industry20th out of 500 stocks 3.3 Analyst's Opinion Consensus RatingCatalent has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $92.40, Catalent has a forecasted upside of 37.9% from its current price of $67.00.Amount of Analyst CoverageCatalent has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.32% of the outstanding shares of Catalent have been sold short.Short Interest Ratio / Days to CoverCatalent has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Catalent has recently increased by 0.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCatalent does not currently pay a dividend.Dividend GrowthCatalent does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalent has received a 72.90% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services", "Clinical research services", and "Pharmacovigilance services" products. See details.Environmental SustainabilityThe Environmental Impact score for Catalent is -0.85. Previous Next 3.1 News and Social Media Coverage News SentimentCatalent has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Catalent this week, compared to 6 articles on an average week.Search Interest14 people have searched for CTLT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows11 people have added Catalent to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $72,064.00 in company stock.Percentage Held by InsidersOnly 0.58% of the stock of Catalent is held by insiders.Percentage Held by Institutions99.38% of the stock of Catalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Catalent are expected to grow by 13.95% in the coming year, from $2.94 to $3.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalent is 28.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.10.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalent is 28.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 95.87.Price to Earnings Growth RatioCatalent has a PEG Ratio of 3.86. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCatalent has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Catalent (NYSE:CTLT) StockCatalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory managRead More Receive CTLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter. Email Address CTLT Stock News HeadlinesFebruary 7, 2023 | finance.yahoo.comCatalent, Inc. Reports Second Quarter Fiscal 2023 ResultsFebruary 6, 2023 | investorplace.comWhy Is Catalent (NYSE:CTLT) Stock Up 20% Today?February 7, 2023 | Investing Trends (Ad)GRAPHITE: "Essential for America's National Defense"Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider. January 30, 2023 | americanbankingnews.comAnalysts Set Catalent, Inc. (NYSE:CTLT) PT at $92.40January 29, 2023 | finance.yahoo.comIs Catalent, Inc.'s (NYSE:CTLT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?January 20, 2023 | finance.yahoo.comCatalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference WebcastJanuary 20, 2023 | finance.yahoo.comReasons for the Decline of Catalent (CTLT) StockJanuary 16, 2023 | finance.yahoo.comCatalent's (CTLT) New Deal to Utilize Its Zydis ODT TechnologyFebruary 7, 2023 | Investing Trends (Ad)GRAPHITE: "Essential for America's National Defense"Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider. January 9, 2023 | finance.yahoo.comAvantor® and Catalent Enter into Multi-Year Supply and Services AgreementJanuary 5, 2023 | finance.yahoo.comSarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy CandidateJanuary 3, 2023 | finance.yahoo.comCatalent, Inc. to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 24, 2022 | finance.yahoo.comAn Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% UndervaluedDecember 22, 2022 | finance.yahoo.comDo You Think Catalent (CTLT) is an Attractive Investment Avenue?December 22, 2022 | finance.yahoo.comWill Catalent (CTLT) Stock Bounce Back?December 19, 2022 | finance.yahoo.comCatalent Announces Changes to its Board of DirectorsDecember 6, 2022 | finance.yahoo.comCatalent (CTLT) Expands Facility Capabilities in ShanghaiNovember 27, 2022 | finance.yahoo.comShould You Add Catalent (CTLT) to Your Portfolio for the Long-Term?November 16, 2022 | finance.yahoo.comBear Of The Day: Catalent (CTLT)November 15, 2022 | finance.yahoo.comHere’s Why Catalent (CTLT) Underperformed in the Third QuarterNovember 11, 2022 | finance.yahoo.comClearBridge Investments’ Worst Q3 Performer: Catalent (CTLT)November 4, 2022 | finance.yahoo.comWhy Shares of Catalent Fell 36% This WeekNovember 3, 2022 | finance.yahoo.comExelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics PipelineNovember 1, 2022 | finance.yahoo.comCatalent (CTLT) Q1 Earnings Lag Estimates, FY23 View CutNovember 1, 2022 | investorplace.comWhy Is Catalent (CTLT) Stock Down 24% Today?November 1, 2022 | finance.yahoo.comCatalent, Inc. Reports First Quarter Fiscal 2023 ResultsNovember 1, 2022 | finance.yahoo.comCatalent (CTLT) Q1 Earnings and Revenues Miss EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CTLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter. Email Address CTLT Company Calendar Last Earnings11/01/2021Today2/07/2023Next Earnings (Confirmed)2/07/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:CTLT CUSIPN/A CIK1596783 Webwww.catalent.com Phone(732) 537-6200Fax732-537-6480Employees19,000Year FoundedN/APrice Target and Rating Average Stock Price Forecast$92.40 High Stock Price Forecast$145.00 Low Stock Price Forecast$58.00 Forecasted Upside/Downside+31.8%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.34 Trailing P/E Ratio29.96 Forward P/E Ratio23.85 P/E Growth3.86Net Income$503 million Net Margins8.83% Pretax Margin10.47% Return on Equity12.55% Return on Assets5.66% Debt Debt-to-Equity Ratio0.87 Current Ratio2.86 Quick Ratio2.08 Sales & Book Value Annual Sales$4.83 billion Price / Sales2.61 Cash Flow$7.28 per share Price / Cash Flow9.63 Book Value$26.76 per share Price / Book2.62Miscellaneous Outstanding Shares179,960,000Free Float178,920,000Market Cap$12.62 billion OptionableOptionable Beta1.26 Key ExecutivesAlessandro MaselliPresident, Chief Executive Officer & DirectorThomas P. CastellanoChief Financial Officer & Senior Vice PresidentKay SchmidtSenior Vice President-Technical OperationsLim Chin WeiManager-Global Scientific AffairsJulien MeissonnierChief Scientific Officer & Vice PresidentKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZDr. Reddy's LaboratoriesNYSE:RDYSarepta TherapeuticsNASDAQ:SRPTLegend BiotechNASDAQ:LEGNTeva Pharmaceutical IndustriesNYSE:TEVAView All CompetitorsInsiders & InstitutionsRetirement Systems of AlabamaSold 1,874 shares on 2/6/2023Ownership: 0.032%Daiwa Securities Group Inc.Bought 2,930 shares on 2/6/2023Ownership: 0.012%Westpac Banking CorpBought 495 shares on 2/6/2023Ownership: 0.007%Ieq Capital LLCBought 1,966 shares on 2/6/2023Ownership: 0.003%Parallel Advisors LLCBought 643 shares on 2/6/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions CTLT Stock - Frequently Asked Questions Should I buy or sell Catalent stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTLT shares. View CTLT analyst ratings or view top-rated stocks. What is Catalent's stock price forecast for 2023? 8 brokerages have issued 1 year price targets for Catalent's stock. Their CTLT share price forecasts range from $58.00 to $145.00. On average, they expect the company's share price to reach $92.40 in the next twelve months. This suggests a possible upside of 37.9% from the stock's current price. View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts. How have CTLT shares performed in 2023? Catalent's stock was trading at $45.01 at the beginning of the year. Since then, CTLT stock has increased by 48.9% and is now trading at $67.00. View the best growth stocks for 2023 here. Are investors shorting Catalent? Catalent saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 5,940,000 shares, an increase of 17.2% from the December 15th total of 5,070,000 shares. Based on an average daily volume of 3,140,000 shares, the days-to-cover ratio is presently 1.9 days. View Catalent's Short Interest. When is Catalent's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023. View our CTLT earnings forecast. How can I listen to Catalent's earnings call? Catalent will be holding an earnings conference call on Tuesday, February 7th at 8:15 AM Eastern. Interested parties can register for or listen to the call using this link. How were Catalent's earnings last quarter? Catalent, Inc. (NYSE:CTLT) issued its quarterly earnings results on Monday, November, 1st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.06. The business had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.01 billion. Catalent had a trailing twelve-month return on equity of 12.55% and a net margin of 8.83%. During the same period in the prior year, the business posted $0.33 EPS. Read the conference call transcript. What is John R. Chiminski's approval rating as Catalent's CEO? 391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees. What other stocks do shareholders of Catalent own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO). What is Catalent's stock symbol? Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT." Who are Catalent's major shareholders? Catalent's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include New York State Common Retirement Fund (0.47%), Tran Capital Management L.P. (0.39%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Norris Perne & French LLP MI (0.14%), Comerica Bank (0.13%) and Mountain Pacific Investment Advisers Inc. ID (0.11%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph. View institutional ownership trends. How do I buy shares of Catalent? Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalent's stock price today? One share of CTLT stock can currently be purchased for approximately $67.00. How much money does Catalent make? Catalent (NYSE:CTLT) has a market capitalization of $12.06 billion and generates $4.83 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.34 on an earnings per share basis. How many employees does Catalent have? The company employs 19,000 workers across the globe. How can I contact Catalent? Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480. This page (NYSE:CTLT) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.